Pulmonary-Allergy Drugs Advisory Committee Meeting Announcement

Pulmonary-Allergy Drugs Advisory Committee Meeting Announcement Committee Meeting September 10, 2013, from 8 a.m. to 3 p.m. The committee will discuss the new molecular entity (NME) new drug application (NDA) 203975 for umeclidinium and vilanterol powder for inhalation (proposed tradename Anoro Ellipta), sponsored by Glaxo Group (d/b/a/ GSK) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.